Malaria vaccine - Crucell/GlaxoSmithKline

Drug Profile

Malaria vaccine - Crucell/GlaxoSmithKline

Alternative Names: Ad35-CS, RTS,S/AS; Ad35.CS.01; Malaria vaccine - Crucell/GSK; Replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01) - Crucell

Latest Information Update: 09 Sep 2015

Price : $50

At a glance

  • Originator Crucell; GlaxoSmithKline
  • Class Antimalarials; Parasitic vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 09 Sep 2015 No recent reports on development identified - Phase-II for Malaria (Prevention, In volunteers) in USA (IM)
  • 06 Sep 2013 Isconova is now called Novavax AB
  • 22 Aug 2013 Isconova has been acquired by Novavax
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top